While retention of the KRAS WT allele in KRAS mutant tumors has emerged as a factor that modulates resistance to MEK and ERK inhibition in preclinical studies [5,17,25], little is known about the distribution of the WT KRAS allele in lung cancers and its clinical implications. This evidence concerns the gene KRAS and lung cancer.